Provectus announces presentation at RBS for full-thickness cutaneous wounds

Provectus Biopharmaceuticals announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium, RBS, active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology, SID, held May 15-18, 2024 in Dallas, Texas. The UTMB team concluded that: The application of multidose 0.01% RBS every other day under ambient light to full-thickness wounds showed: No toxicity or mortality, No loss in body weight, No organ abnormalities, and No observed adverse effect level at the highest tested dose, Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function, Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing, Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure, RBS treatment: Accelerated wound closure, Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, and Reduced angiogenesis after wound closure, which is beneficial in preventing fibrosis.